guest ::
| Home > Publications database > Multi-Institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy. > print |
| Home > Publications database > Multi-Institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy. > print |
| 001 | 307385 | ||
| 005 | 20260218120819.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ijrobp.2025.12.018 |2 doi |
| 024 | 7 | _ | |a pmid:41422918 |2 pmid |
| 024 | 7 | _ | |a 0360-3016 |2 ISSN |
| 024 | 7 | _ | |a 1879-355X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-03029 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Fuchs, Frederik |b 0 |
| 245 | _ | _ | |a Multi-Institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1766416891_3634861 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub / Autoren checken |
| 520 | _ | _ | |a Stereotactic ablative body radiation therapy (SABR) is commonly delivered in multiple fractions, whereas single-fraction (SF) SABR remains uncommon. Magnetic resonance (MR) guided linacs provide superior soft-tissue contrast compared to cone-beam computed tomography on conventional linacs, online adaptive replanning, continuous intrafraction visualization, and automatically triggered beam delivery, potentially enabling safe and effective SF-SABR.We retrospectively analyzed patients treated with MR-guided SF-SABR on a 0.35 Tesla MR-linac at two centers in XXX and XXX (anonymized for review). Median SF-SABR doses were 28 Gy (range: 28-40 Gy) for liver lesions, 30 Gy (range: 28-34 Gy) for lung lesions, 25 Gy for adrenal gland lesions and lymph nodes, and 26 Gy (range: 25-26 Gy) for renal lesions. Endpoints included local control (LC), progression-free survival (PFS), overall survival (OS), and toxicity graded according to CTCAE v5.0.Between April 2020 and December 2024, 161 patients with 175 lesions underwent MR-guided SF-SABR. Lesion distribution was liver (48.0%), lung (42.9%), adrenal gland (4.3%), lymph nodes (3.4%), and kidney (1.9%). Median gross tumor volume (GTV) and planning target volume were 2.4 cc (range: 0.2-83.3 cc) and 9.3 cc (range: 1.4-112.1 cc), respectively. At a median follow-up of 19.3 months, LC rates at 1 and 2 years were 99.1% and 93.6%, respectively. PFS rates at 1 and 2 years were 59.3% and 51.4%, while OS rates were 81.8% and 73.4%, respectively. Treatment was well tolerated, with only one acute grade 3 toxicity reported and no acute grade 4-5 or late grade 3-5 toxicities. Colorectal primary tumors were associated with poorer LC (HR 0.226; p=0.023). Larger GTV independently correlated with reduced LC (HR 1.15; p=0.048) and OS (HR 1.05; p=0.001).MR-guided SF-SABR is feasible, safe, and effective across various tumor locations, providing favorable LC with minimal toxicity, warranting further prospective evaluation. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Herrera, Roberto |b 1 |
| 700 | 1 | _ | |a Kotecha, Rupesh |b 2 |
| 700 | 1 | _ | |a Rubens, Muni |b 3 |
| 700 | 1 | _ | |a Roy, Mukesh |b 4 |
| 700 | 1 | _ | |a Mittauer, Kathryn E |b 5 |
| 700 | 1 | _ | |a Mansoorian, Sina |b 6 |
| 700 | 1 | _ | |a Kaiser, Adeel |b 7 |
| 700 | 1 | _ | |a Kalman, Noah |b 8 |
| 700 | 1 | _ | |a Gaasch, Aurelie |b 9 |
| 700 | 1 | _ | |a Marschner, Sebastian N |b 10 |
| 700 | 1 | _ | |a Bassiri, Nema |b 11 |
| 700 | 1 | _ | |a Rogowski, Paul |b 12 |
| 700 | 1 | _ | |a Eze, Chukwuka |b 13 |
| 700 | 1 | _ | |a Belka, Claus |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Corradini, Stefanie |b 15 |
| 700 | 1 | _ | |a Chuong, Michael D |b 16 |
| 773 | _ | _ | |a 10.1016/j.ijrobp.2025.12.018 |g p. S0360301625066052 |0 PERI:(DE-600)1500486-7 |p nn |t International journal of radiation oncology, biology, physics |v nn |y 2025 |x 0360-3016 |
| 856 | 4 | _ | |y OpenAccess |u https://inrepo02.dkfz.de/record/307385/files/1-s2.0-S0360301625066052-main.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://inrepo02.dkfz.de/record/307385/files/1-s2.0-S0360301625066052-main.pdf?subformat=pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:307385 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-31 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J RADIAT ONCOL : 2022 |d 2024-12-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-31 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-31 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J RADIAT ONCOL : 2022 |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-31 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-31 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-31 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK Koordinierungsstelle München |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|